Article
ISTA to try again after FDA panel rejects Vitrase
Irvine, CA-ISTA Pharmaceuticals is regrouping after an FDA advisory committee said the company's tests of ovine hyal-uronidase (Vitrase) failed to demonstrate sufficient statistical evidence to support its efficacy in treating vitreous hemorrhage.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
